동물용 백신 시장 보고서 : 백신 종류, 기술, 투여 경로, 유통 채널, 지역별(2025-2033년)

The global veterinary vaccines market size reached USD 14.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 29.6 Billion by 2033, exhibiting a growth rate (CAGR) of 7.71% during 2025-2033. The market is driven primarily because of the growing focus on veterinary healthcare, need for livestock insurance and the launch of new veterinary vaccinations. At present, North America dominates the market because of the rising number of pet parents, advanced veterinary healthcare infrastructure, and significant livestock industry.

Veterinary vaccines represent bio-prepared immunizations that are administered to domestic animals or wild species through parenteral and oral routes to stimulate protective immune responses without causing the disease itself. They involve inactivated, live attenuated and recombinant vaccines as some common medications. These inoculations aid in reducing animal suffering, enhancing immune efficiency, and preventing the risk of developing and transmitting various contagious zoonotic diseases.

Veterinary Vaccines Market Trends:

Growing focus on veterinary healthcare

According to the IMARC Group's report, the global veterinary healthcare market reached USD 43.3 Billion in 2023. As more individuals are becoming pet parents, there is a greater emphasis on their well-being, resulting in increased veterinary appointments and preventive treatment. Vaccinations are an important aspect of keeping pets healthy, which is driving the demand for veterinary vaccinations. The growing awareness among the masses about the necessity of preventing animal diseases rather than simply treating them is offering a favorable veterinary vaccines market outlook. Vaccination is a very efficient preventive measure, making it an essential component of veterinary healthcare regimens for both companion animals and cattle. Pet parents and livestock producers are willing to pay more on healthcare, including vaccines, to prevent diseases that could harm animal health and productivity. This tendency is catalyzing the demand for a wide variety of immunizations, particularly as veterinary services become more accessible.

Increasing demand for livestock insurance

The IMARC Group's report shows that the global livestock insurance market reached USD 3.6 Billion in 2023. Many livestock insurance policies demand vaccinations against common diseases as a condition of coverage. Insured farmers and livestock owners are incentivized to vaccinate their animals to meet policy obligations, which is positively influencing the veterinary vaccines market share. Livestock insurance is generally used to reduce the financial risks connected with livestock loss caused by disease, accidents, or natural catastrophes. Farmers who vaccinate their animals lessen the chance of disease outbreaks, making their livestock more insurable and lowering the possibility of claims. This encourages regular vaccinations, which increases vaccine demand.

New launches

New veterinary vaccinations are being produced to combat developing diseases and newly discovered pathogens impacting animals. As outbreaks of previously unknown or developing illnesses are arising, the demand for novel vaccines is rising, thereby propelling veterinary vaccines market growth. Next-generation vaccines, such as recombinant, DNA, and vector-based vaccinations, improve the efficacy and safety of disease prevention in animals. These new vaccines are frequently more effective, have fewer side effects, and give longer-lasting protection, making them more appealing to physicians and pet owners. New releases frequently feature vaccines that cover many diseases or strains in a single shot, making life easier for vets and owners.

Key Market Segmentation:

Breakup by Vaccine Type:

• Livestock Vaccines
  • Bovine Vaccines
  • Poultry Vaccines
  • Porcine Vaccines
  • Others
• Companion Animal Vaccines
  • Canine Vaccines
  • Feline Vaccines
  • Equine Vaccines

Breakup by Technology:

• Attenuated Live Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Others

Breakup by Route of Administration:

• Subcutaneous
• Intramuscular
• Intranasal

Breakup by Distribution Channel:

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies and Drug Stores
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global veterinary vaccines market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

• Boehringer Ingelheim International GmbH
• Ceva Sante Animale
• Elanco Animal Health Incorporated
• Hester Biosciences Limited
• HIPRA
• Indian Immunologicals Limited
• Merck & Co. Inc.
• Neogen Corporation
• Phibro Animal Health Corporation
• Virbac SA
• Zoetis Inc.

Key Questions Answered in This Report:

• How has the global veterinary vaccines market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global veterinary vaccines market?
• What are the key regional markets?
• What is the breakup of the market based on the vaccine type?
• What is the breakup of the market based on the technology?
• What is the breakup of the market based on the route of administration?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global veterinary vaccines market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Veterinary Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Vaccine Type

• 6.1 Livestock Vaccines
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Bovine Vaccines
    • 6.1.2.2 Poultry Vaccines
    • 6.1.2.3 Porcine Vaccines
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 Companion Animal Vaccines
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Canine Vaccines
    • 6.2.2.2 Feline Vaccines
    • 6.2.2.3 Equine Vaccines
  • 6.2.3 Market Forecast

7 Market Breakup by Technology

• 7.1 Attenuated Live Vaccines
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Inactivated Vaccines
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Toxoid Vaccines
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Recombinant Vaccines
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Route of Administration

• 8.1 Subcutaneous
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Intramuscular
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Intranasal
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Veterinary Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Veterinary Clinics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Pharmacies and Drug Stores
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Boehringer Ingelheim International GmbH
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Ceva Sante Animale
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Elanco Animal Health Incorporated
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
  • 15.3.4 Hester Biosciences Limited
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
  • 15.3.5 HIPRA
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Indian Immunologicals Limited
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Merck & Co. Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
  • 15.3.8 Neogen Corporation
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Phibro Animal Health Corporation
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Virbac SA
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
  • 15.3.11 Zoetis Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials